Redox imbalance has long been recognised to be a factor in the pathology of rheumatoid arthritis. There is increasing evidence that reactive species of oxygen, nitrogen and sulphur play biphasic roles in inflammation and may have disease aggravating or ameliorating effects, depending on the dose, tissue compartment and disease phase. A promising target both for therapeutic purposes and as disease markers is the thioredoxin family of redox enzymes, including thioredoxins, thioredoxin reductases and peroxiredoxins. Through its cytokine-like properties, thioredoxin has been proposed to be pro-inflammatory in rheumatoid arthritis. Yet, administration of recombinant thioredoxin appears to ameliorate the disease. We demonstrated recently that protein levels of peroxiredoxin 2 are increased in peripheral blood lymphocytes in rheumatoid arthritis compared with healthy subjects. Therapeutically targeting peroxiredoxins in rheumatoid arthritis provides a new avenue for biomedical research.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)